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Genome-wide association studies (GWAS) testing several hundred thousand SNPs have been performed in
multiple sclerosis (MS) and other complex diseases. Typically, the number of markers in which the evidence
for association exceeds the genome-wide significance threshold is very small, and markers that do not
exceed this threshold are generally neglected. Classical statistical analysis of these datasets in MS revealed
genes with known immunological functions. However, many of the markers showing modest association
may represent false negatives. We hypothesize that certain combinations of genes flagged by these markers
can be identified if they belong to a common biological pathway. Here we conduct a pathway-oriented analysis
of twoGWAS inMS that takes into account all SNPswith nominal evidence of association (P < 0.05). Gene-wise
P-values were superimposed on a human protein interaction network and searches were conducted to identify
sub-networks containing a higher proportion of genes associated with MS than expected by chance. These
sub-networks, and others generated at random as a control, were categorized for membership of biological
pathways. GWAS from eight other diseases were analyzed to assess the specificity of the pathways identified.
In the MS datasets, we identified sub-networks of genes from several immunological pathways including cell
adhesion, communication and signaling. Remarkably, neural pathways, namely axon-guidance and synaptic
potentiation, were also over-represented in MS. In addition to the immunological pathways previously ident-
ified, we report here for the first time the potential involvement of neural pathways in MS susceptibility.
INTRODUCTION
The usefulness of genome-wide association studies (GWAS)
to discover common genetic variants associated with suscepti-
bility to complex diseases has been empirically demonstrated
(1). The aim of these studies is to characterize the genetic
architecture of complex genetic traits through the identifi-
cation of such disease variants against the background of
random variation seen in a population as a whole. In a
typical GWAS, hundreds of thousands of markers are tested
simultaneously in cases and controls and the allelic frequen-
cies of each marker are compared between the two groups.
However, because of the exceedingly large multiple testing
involved in these studies, very few exceed the genome-wide
significance threshold and those that do not exceed this strin-
gent statistical requirement are generally neglected. In many
cases where loci with small but measurable genetic effects
are involved, it is likely that, accepting the null hypothesis
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of no association represents a type II error. A notable example
of this situation can be illustrated by the confirmed association
of PPARG variants in type 2 diabetes (T2D) (2). Due to its
modest effect on disease susceptibility (odds ratio 1.2), this
true association was overlooked by four out of five studies
designed to replicate the initial finding. A similar scenario
was more recently found with IL7R in multiple sclerosis
(MS) (3). In this paper, we aim to show that while individual
modest genetic effects are difficult to ascertain, they can be
collectively identified by combining nominally significant evi-
dence of genetic association with current knowledge of bio-
chemical pathways.
MS is the most common acquired neurological disease of
young adults with a prevalence of approximately 1:1000 in
population groups of northern-European ancestry. MS is
characterized by a variable state of relapsing or progressive
neurological disability that ensues as the consequence of an
autoimmune attack against myelin in the central nervous
system (CNS) (4). Compelling data indicate that susceptibility
to MS is in part inherited (5–8). In addition to the strong effect
of HLA-DRB1, the recently reported GWAS in MS identified
and confirmed the involvement of the genes IL2RA and
IL7RA in disease susceptibility (9). However, as in other
studies of this kind, many associations with markers that
were nominally significant but did not reach the genome-wide
significance threshold were not pursued any further. It is likely
that a significant proportion of these rejected associations are
false negatives, and methods of interpretation are needed that
allow such associations to be recognized.
We hypothesize that meaningful combination of genes har-
boring markers with only modest evidence of association can
be identified if they belong to the same biological pathway or
mechanism. In addition to the single-locus associations ident-
ifiable by standard genome-wide analysis, this type of analysis
can reveal a statistical enrichment of associations within
known biological pathways. The methods presented here
may be useful to identify pathways and networks whose invol-
vement in disease susceptibility are consistent with current
models of pathogenesis, but most importantly may also ident-
ify statistically over-represented but unexpected pathways
revealing novel disease mechanisms.
Inspired in part by analytical advances in the study of gene
expression, we propose a pathway-oriented analysis for
GWAS. We apply a method similar to the one that uses
gene ontologies (10) to analyze a list of differentially
expressed genes, but replacing the measure of differential
expression for each gene by a P-value that indicates the
strength for the association of a gene with the disease pheno-
type. It is important to note that in this adaptation of the
method, two sets of P-values are computed: one set for assess-
ment of the association of each SNP with the trait and another
set for comparison of the observed and expected number of
moderately associated genes in a GO or biological pathway.
The second stage requires that evidence of association at all
the marker loci genotyped within each gene be reduced to a
single, gene-wise P-value.
A limited number of studies have used network-based algor-
ithms to prioritize candidate loci in genetic studies (11–14).
However, these studies either do not use actual genetic (geno-
typic) data or are applied to model organisms. The only study
to date that uses pathway-based analysis of GWAS data does
not consider a protein interaction network (PIN) to further
restrict the possible combinations of causal genes (15).
In this article, we describe a network-based pathway analy-
sis of two GWAS in MS (3,9), where evidence for genetic
association is combined with evidence for protein–protein
interaction. The rationale for performing a pathway-based
analysis in a GWAS lies in the assumption that several
genes, each modestly associated with the disease, may interact
synergistically to confer susceptibility. We carry out extensive
statistical validations and apply the same approach to other
published GWAS to demonstrate the potential utility of this
method.
RESULTS
GWAS results from two MS studies were analyzed to identify
modestly associated variants within genes with related biologi-
cal functions. The first dataset was produced by the Inter-
national MS Genetics Consortium (IMSGC), and comprises
931 family trios genotyped with the GeneChipw Human
Mapping 500K Array Set (Affymetrix) (9). Quality control
for this dataset included sample genotyping efficiency, assess-
ment of marker heterozygosity and allelic frequency, depar-
ture from Hardy–Weinberg equilibrium, gender consistency,
reproducibility and population genetic structure. A total of
334 923 SNPs survived the quality control protocol and were
tested for association with the trait. As expected, a number
of markers in the HLA region were strongly associated with
the disease phenotype. In addition, 78 markers outside the
HLA region were found to exceed the P, 1  1024 genome-
wide threshold of significance. The second dataset (the
GeneMSA study, (3)] was generated using the Sentrixw
HumanHap550 BeadChip (Illumina). After a similar quality
control protocol, 551 642 SNPs were used to conduct an
association analysis using the genotypic test in 978 cases
and 883 controls (3). In addition, the association of each indi-
vidual marker with the disease was tested by fitting a logistic
regression genotypic model in which gender, Center of sample
origin and HLA-DRB11501 status were included as covari-
ates. In the GeneMSA study, 87 SNPs outside of the HLA
region exceeded the genome-wide significance threshold of
P , 1  1024. Although there was no full overlapping of
associated markers between the two studies, several genes
showed evidence of association in both (3). A meta-analysis
is being conducted and will be reported in the near future.
To carry out the protein interaction network-based pathway
analysis (PINBPA), we computed a single P-value for each
gene (the gene-wise P-value, Fig. 1) and overlapped these
onto a curated PIN. Many markers map within gene deserts
or unannotated genes, and these were excluded from the
present analysis. This process resulted in gene-wise P-values
for 14 442 and 17 342 genes for the GeneMSA and IMSGC
GWAS, respectively. We next conducted sub-network
searches on the two MS GWAS using the Cytoscape plugin
jActive modules. jActive modules combines the network pos-
ition and association P-value of each gene to extract poten-
tially meaningful sub-networks or modules. In addition to
searching for significant modules using both datasets together,
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we also conducted individual searches for each study (data not
shown). Although the same basic modules were identified in
both strategies, higher scores were obtained when both data-
sets were used together, suggesting a real power gain when
larger datasets are used. To assess the specificity of the
modules associated with MS, we also performed equivalent
analyses on recent GWAS from other autoimmune diseases
(rheumatoid arthritis, RA; Crohn’s disease, CD; type 1 dia-
betes, T1D), neurological diseases (Alzheimer’s disease,
AD; bipolar disorder, BP) and unrelated diseases (coronary
artery disease, CAD; hypertension, HT; T2D) (16). We
observed statistically significant modules in all diseases
(Fig. 2). Interestingly, the largest number of significant
modules was observed in MS, suggesting greater genetic het-
erogeneity in this disease when compared with others. To test
to what extent significant network modules could be obtained
by chance, we conducted 10 searches randomizing the
P-values among the same set of genes (those with association
P-values ,0.05). With the notable exception of MS, RA and
AD, the module scores obtained from the randomized
P-values were equal to or even higher than those obtained
using the real P-values (Fig. 2A). This observation suggests
that many of these modules do not represent bona-fide biologi-
cal networks and that their high scores may have been
obtained by chance. In contrast, significantly fewer modules
were identified in the searches based on randomized
P-values for MS, RA and AD suggesting that the significant
modules obtained from the real P-values in these diseases rep-
resent biologically meaningful networks. To examine in detail
the magnitude of the scores for real and randomized P-values,
we plotted those of the top 20 modules for each set of P-values
for each disease (Fig. 2B). As expected from the previous
analysis in MS, RA and AD, most of the top 20 modules
obtained with real P-values showed higher scores than the
average score of the randomized searches. In the case of
RA, only the top two modules show significantly higher
scores than the average of their randomized searches
(Fig. 2B). Notably, these two (partly overlapping) modules
are composed exclusively of HLA genes, in which association
with the disease is highly significant. Although the total
number of modules obtained using real P-values in BD and
CD do not differ significantly from those obtained with the
randomized P-values (Fig. 2A), 18 of the top 20 scores were
higher for the real P-values (Fig. 2B). Altogether, these
results suggest that the significant modules found with the
original data may represent real effects of interacting proteins
on each disease phenotype.
Significant modules for MS
We identified 346 significant modules on the basis of their
aggregate degree of genetic association with MS. Due to the
nature of the search algorithm, several of these modules
overlap extensively in their component genes. Thus, to describe
modules representative of association with MS, we selected
those with the highest scores which also displayed a
minimum degree of overlap (Fig. 3). Consistently with all pre-
vious genetic studies inMS, themost significantmodule (MS_I)
included several HLA genes (Fig. 3A). Although the only gene
consistently found associated to MS in this region is
HLA-DRB1, the module shown lists another gene,
HLA-DRA, as its most significant node. It is possible that
because HLA-DRB1 is highly polymorphic, most SNP
markers included in large-capacity arrays are not targeting
this gene directly. Indeed, there are three times as many SNPs
in HLA-DRA as there are in HLA-DRB1 in the Illumina
550 k platform and the DRA SNP rs313588 tags with high sen-
sitivity the HLA-DRB11501 allele. The observed associations
with other HLA genes like HLA-DMA/B and HLA-DOA/B
may be also due to the extensive linkage disequilibrium (LD)
seen in this region. Interestingly, HLA-DRB5, present in the
most significant module, is part of the DR15 haplotype and
has been identified as a potential modifier of the disease
(17,18). The other two HLA genes that are part of the DR15
haplotype (DQA and DQB) are not present in the module
shown. Although the P-values for each of these genes exceed
the threshold of significance used for this analysis, they are
not part of module MS_I because there is no evidence that
they physically interact with any of its components. Not surpris-
ingly, a KEGG pathway search with these genes identified the
terms ‘antigen processing’, ‘cell adhesion molecules’ and
‘Immune system’ as the most significantly over-represented,
Figure 1. Strategy. A gene-wise P-value for association with MS in two inde-
pendent studies was computed by selecting the P-value of the most significant
marker within each gene. Genes with a P-value less than or equal to 0.05 (red
circles) were selected for subsequent analysis. Significant P-values were
loaded as attributes of the PIN and visualized using Cytoscape. The size of
each network node displayed is proportional to its degree of significance.
The plugin Jactive modules was used to identify sub-networks of interacting
gene products that were also associated with the disease. Each significant
module was tested for enrichment in KEGG pathways.
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relative to the number of genes in these pathways expected in
the module by chance (Table 1).
Figure 3B shows another highly significant module charac-
teristic of MS. In this module (MS_II), several HLA genes are
also prominent members, but by virtue of highly connected
molecules such as CD4, CD82 and ITGB2, a more extensive
immune pattern emerged. Interestingly, two non-HLA suscep-
tibility genes previously associated with MS (IL2Ra and
CD58) also appear in this module. We hypothesize that in
addition to its own significance, the presence of IL2Ra in
this module may result from its physical interaction with
STAT3 and ITGB2, which themselves show modest associ-
ation with MS. CD58 was initially identified as a susceptibility
gene in the IMSGC study (9) and its expression was recently
found to be upregulated in peripheral blood cells during
disease relapses (19). In contrast, IL7Ra, another gene recently
identified as a susceptibility factor in MS (20) is not part of
this module. We speculate that it may act through an indepen-
dent pathway. Although several of the other immune-related
genes in this module have not been formally associated with
MS, their involvement in disease pathology seems plausible.
These include several cell adhesion (ITGB2, ITGA4,
ITGA6, ITGAM and ICAM1) and signaling molecules
(TGFBR2, TNFRSF10A and STAT3). Notably, ITGAM
(CD11b) has been recently associated with susceptibility to
systemic lupus erythematosus, another autoimmune disease
(21). KEGG pathways analysis with genes from module
MS_II revealed statistically significant over-representation of
the processes of cell adhesion, leukocyte transendothelial
migration and antigen processing (Table 1).
Figure 2. Module identification. (A) Number of significant modules (size ,50 and score .3) identified by Jactive modules in MS and in a panel of other auto-
immune (RA, T1D and CD), other neurological (AD and BD), and other unrelated (T2D, HT and CAD) diseases. Each disease is represented by a different color.
Filled bars correspond to the results obtained when real P-values were used to search for modules. Open bars are the results obtained with randomized P-values.
(B) Scores of the top 20 modules obtained with real (solid symbols) or randomized (open symbols) P-values for each disease. The average and standard deviation
of 10 randomizations is shown for each disease.
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Interestingly, the other two modules characteristic of MS
(MS_III and MS_IV) suggest a neural component in the sus-
ceptibility to the disease. Module MS_III is highly enriched
with genes typically expressed in neurons and glia (NCK2,
EPHA3, EPHA4, FYN, EFNB1, EFNB2 and EPHB2). Simi-
larly, module MS_IV includes seven glutamate receptors
(GluRs) (GRIK1, GRIK2, GRIK4, GRIA1, GRIA4, GRIN2A
and GRID2) in addition to HOMER1, DLG1 and DLG2.
HOMER1 regulates group 1 metabotropic GluR function,
and DLG1 and DLG2 interact at postsynaptic sites to form a
multimeric scaffold for the clustering of receptors, ion chan-
nels and associated signaling proteins. The identification of
the latter two modules in MS suggests for the first time that
modestly significant associations in genes involved in neural
pathways may contribute to the overall susceptibility to this
disease. Indeed, when members of these modules were
tested for membership to KEGG pathways, highly significant
enrichment in axon guidance pathways (module MS_III) and
long-term depression and potentiation pathways (module
MS_IV) were detected (Table 1).
As a control for our interpretation of these genes in MS, we
next conducted similar analyses on the modules identified for
other diseases. Interestingly, for two of the three autoimmune
diseases tested (RA and T1D), the most significant modules
were exclusively composed of HLA genes (Fig. 4). On the
other hand, only genes involved in the JAK-STAT signaling
pathway (GRB2, JAK1, STAT3 and IFNAR1), and extracellu-
lar matrix-receptor interactions (CD44, COL4A2, COL1A1
and FN1), but not HLA were identified in the third auto-
immune disease (CD). The two genes most robustly associ-
ated with CD (NOD2 and IL23R) are not part of the
selected module. As described for module MS_II, this may
Figure 3. Representative modules for MS. Nodes represent proteins and connections represent physical interactions as determined by the curated human PID
reported in Rual et al. (44). The size of each node is proportional to the 2log (10) P-value of association (A, inset). Nodes are colored by chromosome (see key).
(A) HLA module. This is the highest scoring module in MS, possibly due to the high significance of HLA-DRA and its interaction with other linked genes in the
HLA region. (B) Extended immune module. In addition to HLA genes, this module contains other immune-related genes with more modest P-values of associ-
ation. The significance of the entire module is possibly the result of the many interactions between these genes. (C) MS neural module 1. Seven genes encoding
axon guidance molecules (indicated by asterisks) are part of this small module. (D) MS neural module 2. Seven glutamate receptors (gene symbols starting with
GR) and two glutamate-related genes (HOMER1 and DLG1) are included in this module (these nine genes indicated by asterisks).
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be due to the fact that evidence for the interaction between
these two genes and the rest of the genes in the module is
lacking. As expected, the great majority of pathways ident-
ified in the significant modules for AD and BD were neural
(Development, Parkinson’s disease and long-term depression).
Table 2 shows the genes and pathways contained in the
statistically significant modules identified for RA, T1D, AD
and BD.
Although possibly representing false discoveries, the top
modules identified for T2D, CAD and HT are also shown
for comparison (Fig. 2B). In T2D, the most significant
module contained genes involved in intracellular signaling
Table 1. Significant modules for MS
Pathway Annotated genes in module Observed Expected P-value
Module MS I
Antigen processing and presentation CD4jHLA-DPA1jHLA-DPB1jHLA-DQA2 4/4 (100%) 43/2361 (1.82%) 1.05E206
Cell adhesion molecules (CAMs) CD4jHLA-DPA1jHLA-DPB1jHLA-DQA2 4/4 (100%) 91/2361 (0.03%) 1.14E205
Type I diabetes mellitus HLA-DPA1jHLA-DPB1jHLA-DQA2 3/4 (75%) 30/2361 (0.01%) 2.69E205
Metabolic disorders HLA-DPA1jHLA-DPB1jHLA-DQA2 3/4 (75%) 78/2361 (0.03%) 3.73E204
Immune system CD4jHLA-DPA1jHLA-DPB1jHLA-DQA2 4/4 (100%) 425/2361 (0.2%) 2.28E203
Signaling molecules and interaction CD4jHLA-DPA1jHLA-DPB1jHLA-DQA2 4/4 (100%) 550/2361 (0.2%) 5.35E203
Human diseases HLA-DPA1jHLA-DPB1jHLA-DQA2 3/4 (75%) 411/2361 (0.2%) 2.87E202
Module MS II
Cell adhesion molecules (CAMs) ICAM1jITGB2jITGA4jHLA-DMBj 14/32 (43.8%) 91/2361 (3.9%) 9.19E211
HLA-DQA2jITGAMjITGA6jCD58jCD2jCD4j
HLA-DPA1jCD226jHLA-DRAjCD28
Immune system ICAM1jIL2RAjTLR2jITGB2jITGA4jHLA-DMBj 20/32 (62.5%) 20/2361 (18%) 6.75E207
HLA-DQA2jCXCL12jCTNNA3jITGAMjCTNNB1j
TNFRSF10AjPTK2jITGA6jCD2j
HLA-DPA1jCD4jCD14jHLA-DRAjCD28
Environmental information processing COL2A1jITGB2jHLA-DMBjCXCL12jPTENjITGAMj 28/32 (87.5%) 28/2361 (44.9%) 1.12E205
CTNNB1jPTK2jZFYVE9jCD2jCD4jCD28jBMP4j
EGFRjICAM1jIL2RAjSOCS2jTGFBR2jITGA4j
HLA-DQA2jSTAT3jTNFRSF10AjITGA6jCD58j
HLA-DPA1jCD226jCD14jHLA-DRA
Cellular processes TLR2jCOL2A1jITGB2jHLA-DMBjCXCL12jPTENj 28/32 (87.5%) 28/2361 (45.6%) 1.25E205
ITGAMjCTNNB1jPTK2jILKjCD2jCD4jCD28jEGFRj
ICAM1jIL2RAjSOCS2jMAGI1jTGFBR2jITGA4j
HLA-DQA2jSTAT3jCTNNA3jTNFRSF10AjITGA6j
HLA-DPA1jCD14jHLA-DRA
Signaling molecules and interaction EGFRjICAM1jIL2RAjTGFBR2jITGB2jCOL2A1j 20/32 (62.5%) 20/2361 (23.3%) 2.46E205
ITGA4jHLA-DMBjHLA-DQA2jCXCL12jITGAMj
TNFRSF10AjITGA6jCD58jCD2jHLA-DPA1j
CD4jCD226jHLA-DRAjCD28
Hematopoietic cell lineage IL2RAjITGA6jCD2jCD4jITGA4jCD14jITGAMj 8/32 (25.0%) 8/2361 (3.0%) 2.61E205
HLA-DRA
Leukocyte transendothelial migration ICAM1jPTK2jITGB2jITGA4jCXCL12jCTNNA3j 8/32 (25.0%) 8/2361 (3.9%) 1.61E204
ITGAMjCTNNB1
Type I diabetes mellitus HLA-DPA1jHLA-DMBjHLA-DQA2jHLA-DRAjCD28 5/32 (15.6%) 5/2361 (1.3%) 2.73E204
Antigen processing and presentation HLA-DPA1jCD4jHLA-DMBjHLA-DQA2jHLA-DRA 5/32 (15.6%) 5/2361 (1.8%) 1.45E203
Human Diseases BMP4jEGFRjSOCS2jMAGI1jTGFBR2j 14/32 (43.8%) 14/2361 (17.4%) 2.50E203
HLA-DMBjPTENjHLA-DQA2jSTAT3jCTNNB1j
HLA-DPA1jCD14jHLA-DRAjCD28
Metabolic disorders SOCS2jHLA-DPA1jHLA-DMBjHLA-DQA2j 6/32 (18.8%) 6/2361 (3.3%) 2.62E203
HLA-DRAjCD28
Focal adhesion EGFRjPTK2jITGA6jILKjCOL2A1jITGA4jPTENj 8/32 (25.0%) 8/2361 (7.1%) 6.56E203
CTNNB1
Cell communication EGFRjPTK2jITGA6jMAGI1jTGFBR2jILKjCOL2A1j 11/32 (14.6%) 11/2361 (14.6%) 1.81E202
ITGA4jPTENjCTNNA3jCTNNB1
Regulation of actin cytoskeleton EGFRjPTK2jITGA6jITGB2jITGA4jCD14jITGAM 7/32 (21.9%) 7/2361 (7.1%) 2.36E202
Adherens junction EGFRjTGFBR2jCTNNA3jCTNNB1 4/32 (2.8%) 4/2361 (2.8%) 4.32E202
Module MS III
Axon guidance NCK2jEPHA4jFYNjEFNB1jEFNB2jEPHB2jEPHA3 7/7 (100%) 102/2419 (4.3%) 1.44E206
Development NCK2jEPHA4jFYNjEFNB1jEFNB2jEPHB2jEPHA3 7/7 (100%) 119/2419 (5.0%) 2.14E206
Module MS IV
Neuroactive ligand-receptor interaction GRIK1jGRIA1jGRIK2jGRIK4jGRID2jGRIN2AjGRIA4 7/9 (77.7%) 201/2419 (8.3%) 1.00E205
Signaling molecules and interaction GRIK1jGRIA1jGRIK2jGRIK4jGRID2jGRIN2AjGRIA4 7/9 (77.7%) 563/2419 (23.2%) 5.37E203
Nervous system GRIA1jGRID2jGRIN2A 3/9 (33.3%) 98/2419 (4.0%) 1.96E202
Environmental information processing ERBB4jGRIK1jGRIA1jGRIK2jGRIK4jGRID2j 8/9 (88.8%) 1077/2419 (44.5%) 2.70E202
GRIN2AjGRIA4
Long-term depression GRIA1jGRID2 2/9 (22.2%) 61/2419 (2.5%) 4.77E202
Long-term potentiation GRIA1jGRIN2A 2/9 (22.2%) 64/2419 (2.6%) 4.77E202
Human Molecular Genetics, 2009, Vol. 18, No. 11 2083
(EGFR and BCR), apoptosis (IGF1R, AVEN and APAF1) and
insulin receptor signaling pathway (IGF1R and IGF2). In HT,
the top scoring module listed genes are almost exclusively
involved in cell communication (EGFR, VAV3 and RAC1).
To assess module specificity, we compared the performance
of each of them in the disease in which they were identified
against its performance across all other diseases. This was
accomplished by tabulating the gene-wise P-value of associ-
ation of each gene in the module with every disease. If a
module reached significance just because it was composed
of large-sized genes, for which relatively low P-values could
be obtained by chance, it would be expected that the same
module be also significant in several or all other diseases,
but modules are significant only in the disease in which they
were originally identified, suggesting they were identified
because they were disease-specific and not due to chance.
As demonstrated in Figure 5, the four most significant
modules identified in MS show almost no association with
any other disease. However, there are some genes that show
strong association with other diseases in addition to MS. In
particular, the HLA genes also show highly significant associ-
ations with both RA and T1D, two autoimmune diseases. Most
notably, several significant genes from modules in AD and BD
are also significant in MS. For example, SNCA, CDC42EP3,
FHL2 and CRMP1 all show P-values ,1  1023 in MS and
AD or BD, but consistently higher P-values for all the non-
neurological diseases. The maximum number of SNPs tested
in these genes ranged from 49 (CRMP1) to 79 (CDC42EP3),
slightly above the median number of 40 SNPs/gene across
the Illumina 550 k array. In contrast, genes such as PARK2,
VAV3, PAK7 and NTRK3 yielded relatively low P-values
(P , 1  1023) across most or all diseases, possibly because
a larger number of SNPs were tested for these genes, and
some achieved significance by chance. Indeed, the number
of SNPs for these genes in the Illumina platform ranges
from 149 (PAK7) to 455 (PARK2).
Finally, we identified the 400 genes in which the gene-wise
P-values varied most widely across diseases, and performed
one-way hierarchical clustering on these P-values to produce
a dendrogram identifying diseases with similar patterns of
genetic association (Fig. 6). The two MS and the two RA
studies clustered almost perfectly with each other and they,
in turn, were grouped together in a looser cluster which also
included T1D (autoimmune) and AD (neurological), but did
Figure 4. Representative modules for other diseases. Same conventions as in Figure 3. (A) RA; (B) T1D; (C) CD; (D) T2D; (E) CAD; (F) HT; (G) AD; (H) BD.
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Table 2. Significant modules for other autoimmune and neurological diseases
Pathway Annotated genes in module Observed Expected P-value
RA
Cell adhesion molecules (CAMs) SELLjHLA-DPA1jCD4jHLA-DPB1j 8/18 (44.4%) 91/2361 (3.8%) 6.06E206
HLA-DMBjSELEjHLA-DQA2jHLA-DRA
Antigen processing and presentation HLA-DPA1jCD4jHLA-DPB1jHLA-DMBj 6/18 (33.3%) 43/2361 (1.8%) 1.07E205
HLA-DQA2jHLA-DRA
Type I diabetes mellitus HLA-DPA1jHLA-DPB1jHLA-DMBjHLA-DQA2j 5/18 (27.7%) 30/2361 (1.2%) 3.16E205
HLA-DRA
Human diseases CBLBjRETjMAPK12jGRB2jHLA-DPA1j 12/18 (66.6%) 411/2361 (17.4%) 6.00E205
HLA-DPB1jPRNPjABL1jHLA-DMBj
HLA-DQA2jPIK3R1jHLA-DRA
Metabolic disorders HLA-DPA1jHLA-DPB1jHLA-DMBj 6/18 (33.3%) 78/2361 (3.3%) 1.54E204
HLA-DQA2jPIK3R1jHLA-DRA
Immune system CBLBjMAPK12jGRB2jHLA-DPA1jCD4j 10/18 (55.5%) 425/2361 (18.0%) 3.14E203
HLA-DPB1jHLA-DMBjHLA-DQA2jPIK3R1jHLA-DRA
Chronic myeloid leukemia CBLBjGRB2jABL1jPIK3R1 4/18 (22.2%) 70/2361 (2.9%) 1.20E202
Signaling molecules and interaction SELLjHLA-DPA1jCD4jHLA-DPB1j 10/18 (55.5%) 550/2361 (23.2%) 2.00E202
HLA-DMBjSELEjHLA-DQA2jHLA-DRAjKDRjGHR
T-cell receptor signaling pathway CBLBjGRB2jCD4jPIK3R1 4/18 (22.2%) 86/2361 (3.6%) 2.00E202
Environmental information processing GRB2jSELLjHLA-DMBjHLA-DQA2jKDRjCBLBj 14/18 (77.7%) 1059/2361
(44.8%)
2.44E202
MAPK12jCD4jHLA-DPA1jHLA-DPB1jSELEj
PIK3R1jHLA-DRAjGHR
VEGF signaling pathway MAPK12jPIK3R1jKDR 3/18 (16.6%) 58/2361 (2.4%) 4.26E202
T1D
ECM-receptor interaction LAMA1jCOL4A2jCOL4A1jHSPG2jCOL1A2jITGA2j 9/31 (29.0%) 67/2419 (2.7%) 3.66E206
ITGA10jITGB1jCOL11A1
Antigen processing and presentation TAP1jHLA-DOAjHLA-DMBjHLA-DOBj 7/31 (22.5%) 47/2419 (1.9%) 2.25E205
HLA-DQA2jHLA-DRAjHLA-F
Type I diabetes mellitus HLA-DOAjHLA-DMBjHLA-DOBjHLA-DQA2j 6/31 (19.3%) 30/2419 (1.2%) 2.25E205
HLA-DRAjHLA-F
Cell Communication TLN1jMAGI3jCOL4A2jCOL4A1jITGA10jITGA2j 15/31 (48.3%) 351/2419 (14.5%) 8.68E205
ITPR3jGRM1jITGB1jITPR1jPXNjLAMA1jTUBBj
COL1A2jCOL11A1
Cellular processes TLN1jITGA10jBCL2L1jHLA-DMBjITGB1jPXNj 26/31 (83.8%) 1098/2419
(45.3%)
1.10E204
TUBBjCASP8jTAP1jHLA-DOAjCOL11A1j
HLA-DOBjMAGI3jCOL4A2jCOL4A1jITGA2j
ITPR3jGRM1jHLA-DQA2jITPR1jHLA-Fj
LAMA1jRIPK1jCOL1A2jAPAF1jHLA-DRA
Focal adhesion LAMA1jCOL4A2jTLN1jCOL4A1jCOL1A2jITGA2j 10/31 (32.2%) 170/2419 (7.0%) 2.43E204
ITGA10jITGB1jCOL11A1jPXN
Cell adhesion molecules (CAMs) HLA-DOAjHLA-DMBjHLA-DOBjITGB1j 7/31 (22.5%) 93/2419 (3.8%) 9.26E204
HLA-DQA2jHLA-DRAjHLA-F
Metabolic disorders HLA-DOAjHLA-DMBjHLA-DOBjHLA-DQA2j 6/31 (19.3%) 79/2419 (3.2%) 2.55E203
HLA-DRAjHLA-F
Signaling molecules and interaction COL4A2jCOL4A1jHSPG2jITGA2jITGA10j 16/31 (51.6%) 563/2419 (23.2%) 3.05E203
HLA-DMBjHLA-DQA2jGRM1jITGB1j
HLA-FjLAMA1jCOL1A2jHLA-DOAjCOL11A1j
HLA-DOBjHLA-DRA
Environmental information processing COL4A2jCOL4A1jHSPG2jITGA2jITGA10jBCL2L1j 23/31 (74.1%) 1077/2419
(44.5%)
3.88E203
ITPR3jHLA-DMBjHLA-DQA2jGRM1jITGB1j
ITPR1jPXNjHLA-FjLAMA1jMAP4K4jTAP1jCASP8j
COL1A2jHLA-DOAjHLA-DOBjCOL11A1jHLA-DRA
Human diseases BCL2L1jHLA-DMBjHLA-DQA2jITGB1jHLA-Fj 13/31 (41.9%) 423/2419 (17.4%) 5.60E203
LAMA1jAPPjTUBBjCASP8jPRNPjHLA-DOAj
HLA-DOBjHLA-DRA
Neurodegenerative disorders LAMA1jAPPjCASP8jBCL2L1jPRNP 5/31 (16.1%) 103/2419 (4.2%) 3.94E202
Gap junction TUBBjITPR3jGRM1jITPR1 4/31 (12.9%) 68/2419 (2.8%) 4.13E202
Prion disease LAMA1jPRNP 2/31 (6.4%) 13/2419 (0.5%) 4.30E202
AD
Neurodegenerative disorders APPjSNCAIPjMAGI1jSNCAjPARK2jITCHjAPBA1 7/26 (26.9%) 103/2419 (4.2%) 3.77E203
Parkinson’s disease SNCAIPjSNCAjPARK2 3/26 (11.5%) 13/2419 (0.5%) 7.93E203
Development EGFRjPAK6jCDC42jPAK7jERBB4jSRGAP1 6/26 (23.0%) 119/2419 (4.9%) 2.30E202
Human diseases EGFRjCDC42jAPPjSNCAIPjMAGI1jTGFBR1jSNCAj
PARK2jITCHjAPBA1jTGFB2
11/26 (42.3%) 423/2419 (17.4%) 3.46E202
BD
Adherens junction EGFRjIGF1RjMAPK1jCREBBPjPTPN1jINSR 6/28 (21.4%) 68/2419 (2.8%) 5.67E203
MAPK signaling pathway EGFRjMEF2CjMAPK1jRPS6KA2jNTRK2jGNA12j 9/28 (32.1%) 219/2419 (9.0%) 1.40E202
PTPRRjNFATC2jCDC25B
Continued
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not include any of the unrelated diseases. Intriguingly, the
study on CD did not cluster with MS and RA, but with the
unrelated diseases. One possible explanation for this differ-
ence is the lack of a strong association with HLA genes in
CD compared with the other autoimmune diseases. Instead,
genetic susceptibility to CD appears to be more widely
spread across the genome (16,22).
DISCUSSION
There is ongoing debate on the exact mechanism of MS patho-
genesis. Some theories support the idea that there is a primary
immune disorder targeting the CNS, with subsequent neurode-
generation being a consequence of the initial inflammatory
process. A competing theory states that neurodegeneration is
the primary cause of the disease, leading to an inflammatory
reaction within the CNS (23). Most previous genetic studies
in MS (by genome-wide or candidate gene approaches) have
involved immune-related genes, thus supporting the first scen-
ario. In this article, we employ a novel network-based pathway
analysis using data from two independent GWAS and impli-
cate neural pathways in the susceptibility to MS.
Recently reported pathway-based analyses of GWAS data
(15,24,25) relayed exclusively on classical biological path-
ways as described in KEGG, Biocarta or gene ontology. The
article by Torkamani et al. (15) is of particular interest since
they analyzed several of the GWAS datasets we used as
control. We also tested a similar approach in which a
literature-derived network of biological relationships is first
assembled and subsequently, an exhaustive search for sub-
networks representing particular pathways is conducted (26).
Using the two MS datasets, this analysis yielded significant
pathways associated with immune and neurological functions
including antigen presentation, axon guidance and neurogen-
esis (Supplementary Material, Table S1). In order to enhance
the potential for discovery of biologically relevant circuits,
we introduced the PIN to the analysis. The PINBPA approach
focuses on the combined effect of associated genes by restrict-
ing the search for pathways to only those gene products that
actually interact as determined by a high-quality PIN. Aside
from significantly reducing the possible total number of inter-
actions, the network-based approach takes advantage of the
fact that if two proteins physically interact, they likely
belong to the same biological pathway. We acknowledge
that restricting the search to only certain interactions also
increases the chances of detecting pathways even in the
absence of significant P-values for association. To account
for this, we performed extensive testing and showed that the
module scores obtained for most diseases were lower and
less reproducible when randomized datasets were used.
Other methods that detect gene–gene interactions have been
described (27–30). However, unlike a network-based
approach, those methods consider all possible pair-wise inter-
actions, limiting the biological interpretation of the data. Fur-
thermore, implementation of this approach at a whole-genome
scale requires extraordinary computational resources. Another
advantage of our pathway analysis approach is that it may
provide a basis for patient stratification by disease subtype.
Whether MS is a single disease or several diseases with a
common phenotype is still a matter of debate. Pathway-based
genetic analyses may help identify different, and even unre-
lated, biological mechanisms as responsible for disease patho-
genesis. The implications of such potential discovery are
broad, as this may lead to targeted therapeutics, and individu-
ally tailored disease management.
The most likely cause for the modest P-values seen in all
diseases analyzed is insufficient power to detect small
genetic effects. It is estimated that the allelic odds ratios of
susceptibility variants in most complex diseases lie between
2.0 and 1.2. For an odds ratio of 2.0, a sample size of 500 indi-
viduals provides 80% power to detect a causative variant with
population frequency of 10% (a ¼ 1  1025, multiplicative
model). However, at an odds ratio of 1.2, 9000 cases and con-
trols are needed to achieve the same power (31). All the
GWAS analyzed here genotyped between 1000 and 2000
cases, thus only providing adequate power to detect relatively
large genetic effects or associations with relatively common
disease-specific markers. Under these conditions, a pathway-
based analysis may compensate for the lack of statistical
power due to insufficient sample size by making use of the
much higher prior probability of true associations among
certain combinations of genes, determined by their biological
relationships, than among other, arbitrary combinations. The
added constraint that only associations between genes that
physically interact (as determined by the PIN) are taken into
account further strengthens the prior.
A necessary step in the search for pathways involves con-
densing the evidence for association for each marker within
a gene into one P-value representative of the gene. Although
for our analysis the gene-wise P-value was that of the most
significant SNP within that gene (min P-value method), we
also explored other methods that would take into account
the variable number of markers genotyped within each gene
and the extent of LD among them. We examined various tech-
niques for correcting the gene-wise P-value for the number of
SNPs per gene, and adjusting the corrected value for LD. We
also applied the Fisher’s method for combining P-values, fol-
lowed by an adjustment for LD. However, when these
Table 2. Continued
Pathway Annotated genes in module Observed Expected P-value
Nervous system IGF1RjMAPK1jRPS6KA2jGNAI1jCREBBPjGNA12 6/28 (21.4%) 98/2419 (4.0%) 1.40E202
Neurodegenerative disorders HDjCREBBPjSNCAjPARK2jBCL2L1jINSR 6/28 (21.4%) 103/2419 (4.2%) 1.40E202
Human diseases EGFRjIGF1RjMAPK1jHDjHNF4AjCREBBPjSNCAj 12/28 (42.8%) 423/2419 (17.4%) 1.78E202
PARK2jBCL2L1jRUNX1jPRKCEjINSR
Long-term depression IGF1RjMAPK1jGNAI1jGNA12 4/28 (14.2%) 61/2419 (2.5%) 4.92E202
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methods were used, a very small number of genes exceeded
the threshold of significance, not enough to compute any
pathway searches. Although such correction and adjustment
are appropriate on the null hypothesis of no associations
genome-wide, it may penalize large genes excessively if true
(causative) associations are proportionally more common in
smaller genes. We also evaluated to what extent larger genes
were more likely to be included in our analysis by virtue of
being more represented in the array. We found no significant
difference in the distribution of gene sizes within a given
module when compared with a random set of genes (Sup-
plementary Material, Fig. S1). Altogether, the min P-value
method provided the most consistent and balanced results.
This method has also been applied by Torkamani et al. (15)
in their pathway analysis of the WTCCC dataset with
similar results.
Here we implicate neural pathways (e.g. axon guidance and
long-term potentiation) in susceptibility to MS. Only one other
article has reported a neural gene in MS susceptibility to date
(32). Due to the power limitations described above, none of
the individual genes in these pathways may exceed the
genome-wide threshold of significance in tests of association.
However, when an entire pathway is considered, even modest
associations in several of its component genes contribute to the
overall P-value. For example, seven GluR genes were found to
be marginally associated with MS (Module MS_IV). Although
each marker may not reach significance when tested in iso-
lation, the probability that several GluRs are identified by
chance, if none of them is truly associated with the disease,
is exceedingly small. Furthermore, not all GluRs are
encoded on the same chromosome, thus reducing the likeli-
hood of inflation of the signal due to LD. The identified associ-
ations between GluRs and MS are of substantial biological
relevance since glutamate is the principal excitatory neuro-
transmitter within the CNS. Glutamate acts on neuronal and
glial ionotropic receptors coupled to specific ligand-gated cat-
ionic channels, and mGluRs, coupled to second messengers.
Under normal conditions, astrocytes maintain low extracellu-
lar glutamate levels by using transporters to take up glutamate
rapidly as high extracellular glutamate levels are neurotoxic.
Indeed, elevated extracellular glutamate levels can result in
the death of neurons and oligodendrocytes through excitotoxic
mechanisms and these have been shown to play a role in the
pathology of MS and EAE (33,34). Interestingly, susceptibility
to excitotoxicity may be under genetic control (35).
A second neural module (MS_III) contained NCK2 and
FYN, in addition to two members of the ephrin family of pro-
teins (EFNB1 and EFNB2) and three or their receptors
(EPHA3, EPHA4 and EPHB2). These genes are involved in
axon guidance, the process during development by which
neurons extend their processes and make connections through-
out the CNS. Specifically, Eph/ephrin signaling regulates axon
guidance through contact repulsion during development of the
CNS, inducing collapse of neuronal growth cones (36). Eph
receptors and ephrins continue to be expressed in the adult
CNS, although usually at lower levels, but have been found
to be upregulated in MS lesions on different cell types, includ-
ing reactive astrocytes, neurons and oligodendrocytes (37).
This upregulated expression may directly inhibit regrowth of
regenerating axons, but Eph expression also regulates astrocy-
tic gliosis and formation of the glial scar. Therefore, Eph/
ephrin signaling may inhibit regeneration by more than one
mechanism and modulation of Eph receptor expression or sig-
naling could prove pivotal in determining the outcome of
injury in the adult CNS.
Due to the nature of the searches performed, this is a gene-
centered analysis, and thus it is possible that true associations
with markers that lie in large intergenic regions were neg-
lected. Also, markers within genes not represented in the
PIN were not evaluated in this analysis. Finally, it is reason-
able to expect that subgroups of patients with shared risk
alleles would be identified by this method. We were unable
to subclassify patients because our analysis only takes into
account the most significant variant for each gene, and more
significant markers may be needed to identify such subgroups.
Nevertheless, there is scope for the development of related
methods to increase the power to detect associations in these
regions and genes. In summary, by following a network-based
Figure 5.Module specificity. The P-values of genes from the representative modules shown in Figures 3 and 4 are displayed as a heatmap. Each row corresponds
to a single gene. Genes are organized by their membership of modules. Genes corresponding to the four modules described for MS (Fig. 3) are at the top, fol-
lowed by genes corresponding to modules from all other diseases. Because modules from different diseases may share one or more genes (e.g. HLA in auto-
immune diseases), these may be represented more than once in the figure. Color-coded bars next to each module mark the genes that the module comprises. The
same color code in the column headers indicates the disease for which the P-values are represented below. In general, genes from modules identified in one
disease show the highest P-values for that disease, and less significant P-values for most other diseases. A notable exception is the HLA genes which show
overlap between MS, RA and T1D, all of which are autoimmune diseases. Interestingly, some of the genes from the AD and BD modules show significant
P-values also in MS.
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pathway analysis, we have expanded the immune-related set
of genes associated with MS. Furthermore, we have identified
neural pathways whose involvement in the disease is biologi-
cally plausible. Larger pathway-oriented association studies
will ultimately be necessary to validate these findings.
MATERIALS AND METHODS
Genetic association data
In total, 11 GWAS were analyzed (two for MS and nine others
as controls). The first of the two studies in MS was a family
trio-based analysis recently published by the International
MS Genetics Consortium (IMSGC) in which 334 923 SNPs
were analyzed in 931 trios by the transmission disequilibrium
test (9). The second MS study (GeneMSA) was a multicenter
case–control association analysis done collaboratively among
the University of California San Francisco, Vrije Universiteit
Medical Center in Amsterdam, University Hospital Basel,
and the pharmaceutical company Glaxo SmithKline (GSK).
The GeneMSA study analyzed 551 642 SNPs in 978 cases
and 883 controls (3).
As controls, we used data from four studies in other auto-
immune diseases, consisting of two studies in RA, and one
each in CD and T1D. Two studies in other neurological dis-
eases included one each in AD and BD. In addition, unrelated
diseases included one study each in HT, CAD and T2D. The
studies for RA, CD, T1D, BD, HT, CAD and T2D were per-
formed by the Wellcome Trust Case Control Consortium
(WTCCC) (16) and the genotypic P-values of association for
each tested SNP were obtained from the project’s webpage
(www.wtccc.org.uk). A second RA study was performed by
Plenge and collaborators in which 317 503 SNPs were tested
in 1522 cases and 1850 controls (38). P-values for association
were obtained from the Supplementary information provided
in that article. Processed data for the AD study performed at
GSK is publicly accessible from http://www.imgw.com/
public/ (39).
Module (sub-network) searches
We first computed the gene-wise significance for association
by choosing the lowest P-value of all SNPs mapping to a
given gene (min P-value method) without correction.
Although this method potentially introduces biases in favor
of larger genes (for which more SNPs are generally typed,
thus increasing the chances of type I error), the use of the
gene-wise P-value as an input variable in a second analysis
step (see Introduction) provides protection against spurious
findings caused by such bias. Moreover, we implemented rig-
orous validation steps that included randomized network
searches and comparison with similar datasets from other
complex diseases. Other measures of gene-wise significance
were considered, including Fisher’s method of combining
P-values (40), and a method that corrects for the number of
SNPs tested within each gene and subsequently adjusts for
LD (41,42) (data not shown). However, since the most biologi-
cally significant findings were obtained with the min P-value
method, we only report on these results.
Genes with a gene-wise association P-value of 0.05 or less
were considered for further study and loaded into the Cytos-
cape software, a package for visualization and analysis of net-
works (43). A curated human PIN (n ¼ 7500) was downloaded
and visualized in Cytoscape (44,45). The gene-wise P-values
for association with each disease were loaded as node attri-
butes of the PIN and the plugin jActive modules (46) was
used to identify sub-networks of modestly associated but inter-
acting gene products. The biological interpretation of a statisti-
cally significant module (sub-network) is that the products of a
set of genes associated to the disease also interact physically,
thus raising the possibility that they belong to the same
pathway or biological process. jActive modules grows a
network from each node by systematically adding one neigh-
bor at a time and computing an aggregate score (S) based on
a given statistical significance, in our case, the gene-wise
P-value of association with the disease. Specifically,
S ¼ ﬃﬃﬃﬃﬃﬃkZp , where each gene P-value is converted to a
Z-score (using the inverse normal CDF) and k is the number
of genes contributing to the score S. Once S ceases to increase
significantly, the sub-network stops growing and is reported as
a module (46). Next, the test statistic (S) is compared with an
appropriate background distribution. As a background distri-
bution, we used the scores of modules randomly selected
from the entire PPI network. Since the background distribution
is dependent on module size, jActive modules creates a back-
ground distribution by scoring 10 000 random modules of each
size (in a Monte Carlo procedure). Furthermore, since the
scores distribution is a smooth function of module size,
jActive modules applies a sliding window average to the back-
ground distribution. As in the original publication, modules
with S . 3 (3 SD above the mean of randomized scores)
were considered significant. It is interesting to note that
scores of up to 12 were obtained for some diseases. If con-
verted back to P-values and corrected for the multiple
Figure 6. Disease hierarchical tree. The P-values of the genes showing the
most variable levels of association across diseases were selected to cluster
the GWAS studies. Studies connected by the same branch of the dendrogram
are more similar to each other than those in different branches. Notably, the
two MS studies cluster together, and with those from RA and T1D. Also,
the two RA studies cluster together (and with T1D, another autoimmune
disease). MS(1), GeneMSA; MS(2), IMSGC; RA(1), Gregersen; RA(2),
WTCCC.
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network searches the algorithm performs (107), results
would remain highly significant (10214) even after the correc-
tion. P-values from both studies in MS (IMSGC and
GeneMSA) and RA (Plenge et al. and WTCCC) were included
in the search, resulting in higher confidence in the significance
of the modules retrieved. To merge datasets, we included
genes with significant P-values in either study, and when a
given gene was present in both, the min P-value was con-
sidered. To evaluate whether the significant modules obtained
were biologically meaningful, we computed their enrichment
in human biochemical pathways (i.e. the proportion of genes
in a specific module that are in a pathway, compared to the
overall proportion of genes described for that pathway)
using the plugin BINGO (47) with a custom ontology and
annotation files derived from the Kyoto Encyclopedia of
Genes and Genomes (KEGG) database. The statistical signifi-
cance for enrichment of a given module in ontologies and
pathways was determined by a chi-square test. Significant
KEGG pathways are reported and visualized as directed
acyclic graphs similar to those commonly reported for the
analysis of GO by many popular gene expression analysis pro-
grams. Using the same plugin, we also computed enrichment
of significant modules in GO categories. The analysis of
several modules resulted in highly significant results with
both KEGG pathways and GO. However, although most
genes with known functions are categorized in the GO
system, this classification is largely based on information
retrieved from the literature while KEGG primarily categor-
izes genes into bona-fide biological pathways. Because bio-
logical interpretation of pathways is more straightforward,
we report only on KEGG results. In addition, we also con-
sulted commercially curated pathway data from Ingenuity
(Redwood City, CA, USA), GeneGo (Encinitas, CA, USA),
NetPro Molecular Connections (Singapore) and Jubilant
(Berkley Heights, NJ, USA).
To account for the possibility that significant modules were
obtained by chance, 10 searches with the gene-based P-values
randomly permuted over the genes were conducted for each
disease. The average score of the randomized searches is com-
pared with the scores obtained with the real (i.e. non-
randomized) P-values for each disease.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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